Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, announced today that Health Canada has approved Abstral®. Abstral® is a novel, rapidly-disintegrating, sublingual (under the tongue) formulation of fentanyl, a well-established opioid used for the management of episodes of breakthrough pain experienced by cancer patients who are already receiving opioid analgesics for chronic pain. Paladin obtained the Canadian rights from ProStrakan Group plc (LSE:PSK) in December 2008.
"The approval of Abstral® is great news for Canadians cancer patients. We are eager to launch Abstral® in the next quarter and add this product to our growing pain portfolio which includes Tridural®, Metadol® and Pennsaid®", said Jonathan Ross Goodman, President & CEO Paladin Labs.
No comments:
Post a Comment